Compare Amgen, Inc. (AMGN) vs Brown-Forman Corporation Class B (BF.B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Brown-Forman Corporation Class B — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while Brown-Forman Corporation Class B trades at $26.27. The key difference: Amgen, Inc. pays a 2.77% dividend while Brown-Forman Corporation Class B pays none, and Amgen, Inc. is trading nearer its 52-week high, Brown-Forman Corporation Class B nearer its low. Which is the better fit depends on your goals.
| AMGN | BF.B | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $31.26 |
52-Week Low | $271.18 | $22.80 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BF.B trades at $26.17, up 3.77% today, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings show three beats out of four quarters, with Q2 2024 EPS of $0.48 exceeding the $0.46 estimate. Analyst consensus is mixed, with 25% buy, 50% hold, and 25% sell ratings, reflecting cautious optimism amid weak valuation ratio data.
The stock faces headwinds from bearish technical trends and incomplete fundamental metrics, but consistent earnings beats provide a positive catalyst. Risks include market volatility and lack of recent news, while institutional sentiment remains divided. Upside depends on future financial disclosures confirming profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →
